Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)

Neuromuscul Disord. 2006 May;16(5):334-6. doi: 10.1016/j.nmd.2006.03.002. Epub 2006 Apr 17.

Abstract

We report two patients with myopathy associated with anti-signal recognition particle Ab, refractory to conventional therapy, who were treated with prednisone and plasma exchange, followed by rituximab. A marked response was observed in both patients, with partial to complete recovery of muscle strength, which was sustained.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody Formation / drug effects
  • Antibody Formation / immunology
  • Autoantibodies / immunology
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Clinical Protocols / standards
  • Disease Progression
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Male
  • Muscle, Skeletal / immunology
  • Muscle, Skeletal / pathology*
  • Muscle, Skeletal / physiopathology
  • Muscular Diseases / diagnosis
  • Muscular Diseases / physiopathology
  • Muscular Diseases / therapy*
  • Plasma Exchange / methods*
  • Prednisone / administration & dosage*
  • Rituximab
  • Signal Recognition Particle / immunology*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies
  • Immunologic Factors
  • Signal Recognition Particle
  • Rituximab
  • Prednisone